Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metformin controlled release - Bristol-Myers Squibb/Merck

Next Previous
X
Search
Drug Profile

Metformin controlled release - Bristol-Myers Squibb/Merck

Alternative Names: Glucophage extended release reduced mass; Glucophage SR; Glucophage XR; Glucophage XR RM; Metformin extended release - Bristol-Myers Squibb; Metformin extended release - Merck; Metformin hydrochloride - Merck; Metformin XR - Bristol-Myers Squibb

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Bristol-Myers Squibb; Merck & Co; Zuellig Pharma
  • Class Antihyperglycaemics; Biguanides; Eye disorder therapies; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in South Korea (PO, Tablet)
  • 03 Jan 2023 Merck & Co completes a phase I bioequivalence trial in Healthy volunteers in Germany (PO) (NCT05463094)
  • 01 Aug 2022 NCT05463094= Feedback incorporated

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top